NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Innoviva, Inc. INVA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$411.3M
▲ 14.7% vs FY2024
Dividend streak
1 yrs
Raised every year since 2025
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
29.1%
Net margin · FY25
65.9%
Dividend coverage
-0.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 411.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
66 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
29.1%
Return on equity, FY2025
ROE
Operating margin39.8%
Net margin65.9%
Return on assets18.5%
Each USD of equity produced 29 cents of profit this year.
Returned to shareholders
USD 2.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 2.0M
Share of profit0.7%
Consecutive raises1 years
USD 2.0M in buybacks — 1% of the year's profit went back to shareholders.
Growth
+4.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.5%
+4.1%
+22.5%
+20.8%
Net income
+7.2%
−1.6%
EPS, diluted
+11.7%
+10.3%
Returned to shareholders
−37.6%
−32.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years−26.4%
Change, 10 years—
The share count shrank 26% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.6B
total assets, end of FY2025
Total assetsUSD 1.6B
EquityUSD 1.2B
CashUSD 550.9M
Gross debtUSD 257.7M
Net debtUSD -293.2M
Current ratio14.64×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.4
0.4
0.3
0.3
0.4
0.3
0.3
0.3
0.2
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.2
0.2
0.1
0.3
0.4
0.4
0.2
0.2
0.2
0.1
0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
EBITDA $B
·
·
·
·
0.5
0.4
0.3
0.3
0.2
0.1
0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
Income tax $B
0.1
0.0
0.0
0.1
0.1
0.1
0.0
−0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
0.3
0.0
0.2
0.2
0.4
0.3
0.2
0.4
0.1
0.1
−0.0
−0.2
−0.2
−0.0
−0.1
−0.1
−0.1
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
0.00
0.00
0.75
0.50
0.00
0.00
·
·
·
Payout %
·
·
·
·
0
0
0
0
0
2
−466
−34
−0
−0
·
·
·
ROE %
29.1
3.4
31.8
44.9
77.3
68.9
81.8
·
·
·
·
−444.7
−75.2
−54.6
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed